Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.480.02%
QQQ
714.89-
BTC/USD
77111.000.2124%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%
Updated: Sep 11, 2026

Analyst Stock Ratings

Analyst initiations occur when coverage begins on a stock. When an analyst initiates coverage, they publish a first rating and price target to help investors understand the opportunity.

Get Alert
No data available to display

Recent Analyst Stock Rating Initiation News

Marvell Stock Is Up 180% This Year: BofA Says the Real AI Opportunity Is 5 Times Bigger
Marvell Stock Is Up 180% This Year: BofA Says the Real AI Opportunity Is 5 Times Bigger
Marvell has nearly tripled in 2026, but BofA's Vivek Arya sees its custom AI market reaching $300 billion by 2030. Buy rating, $365 price target.
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.
Lovesac Analysts Cut Their Forecasts After Q2 Earnings
Lovesac Analysts Cut Their Forecasts After Q2 Earnings
Lovesac beat Q2 EPS estimates but missed sales; raised FY27 EPS guidance, cut revenue outlook, and analysts lowered price targets.
PRO
Morgan Stanley Maintains Overweight on RH, Lowers Price Target to $210
Morgan Stanley analyst Simeon Gutman maintains RH (NYSE:RH) with a Overweight and lowers the price target from $240 to $210.
PRO
Morgan Stanley Maintains Equal-Weight on SolarEdge Technologies, Lowers Price Target to $33
Morgan Stanley analyst David Arcaro maintains SolarEdge Technologies (NASDAQ:SEDG) with a Equal-Weight and lowers the price target from $35 to $33.
PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $182 to $183.
PRO
Morgan Stanley Maintains Equal-Weight on Avis Budget Gr, Lowers Price Target to $95
Morgan Stanley analyst Andrew Percoco maintains Avis Budget Gr (NASDAQ:CAR) with a Equal-Weight and lowers the price target from $99 to $95.
PRO
Morgan Stanley Maintains Overweight on Aurora Innovation, Raises Price Target to $18
Morgan Stanley analyst Ravi Shanker maintains Aurora Innovation (NASDAQ:AUR) with a Overweight and raises the price target from $14 to $18.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved